Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Jan 15;98(1):4-8.
doi: 10.1038/sj.bjc.6604098. Epub 2008 Jan 8.

Updates on p53: modulation of p53 degradation as a therapeutic approach

A Dey  1 , C S Verma, D P Lane
Affiliations
Review

Updates on p53: modulation of p53 degradation as a therapeutic approach

A Dey et al. Br J Cancer. .

Abstract

The p53 pathway is aberrant in most human tumours with over 50% expressing mutant p53 proteins. The pathway is critically controlled by protein degradation. Here, we discuss the latest developments in the search for small molecules that can modulate p53 pathway protein stability and restore p53 activity for cancer therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Small molecules that modulate p53 degradation and stability.
See this image and copyright information in PMC

References

    1. Bertheau P, Plassa F, Espie M, Turpin E, de Roquancourt A, Marty M, Lerebours F, Beuzard Y, Janin A, de The H (2002) Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 360: 852–854 - PubMed
    1. Bond GL, Hu W, Levine AJ (2005) MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 5: 3–8 - PubMed
    1. Brummelkamp TR, Fabius AW, Mullenders J, Madiredjo M, Velds A, Kerkhoven RM, Bernards R, Beijersbergen RL (2006) An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2: 202–206 - PubMed
    1. Chen D, Zhang Z, Li M, Wang W, Li Y, Rayburn ER, Hill DL, Wang H, Zhang R (2007) Ribosomal protein S7 as a novel modulator of p53–MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene 26: 5029–5037 - PubMed
    1. Chene P (2003) Inhibiting the p53–MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 3: 102–109 - PubMed

Publication types

Substances